Lipid metabolism disorders and bone dysfunction - interrelated and mutually regulated (Review)
- Authors:
- Li Tian
- Xijie Yu
-
Affiliations: Laboratory of Endocrinology and Metabolism, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China - Published online on: March 11, 2015 https://doi.org/10.3892/mmr.2015.3472
- Pages: 783-794
-
Copyright: © Tian et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
This article is mentioned in:
Abstract
Bagger YZ, Tankó LB, Alexandersen P, Qin G and Christiansen C: Prospective epidemiological risk factors study group: radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med. 259:598–605. 2006. View Article : Google Scholar : PubMed/NCBI | |
Sinnott B, Syed I, Sevrukov A and Barengolts E: Coronary calcification and osteoporosis in men and postmenopausal females are independent processes associated with aging. Calcif Tissue Int. 78:195–202. 2006. View Article : Google Scholar : PubMed/NCBI | |
Yao W, Cheng Z, Busse C, Pham A, Nakamura MC and Lane NE: Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis and Rheum. 58:1674–1686. 2008. View Article : Google Scholar | |
Edwards CJ, Hart DJ and Spector TD: Oral statins and increased bone-mineral density in postmenopausal females. Lancet. 355:2218–2219. 2000. View Article : Google Scholar : PubMed/NCBI | |
Barengolts EI, Berman M, Kukreja SC, Kouznetsova T, Lin C and Chomka EV: Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal females. Calcif Tissue Int. 62:209–213. 1998. View Article : Google Scholar : PubMed/NCBI | |
Consensus development conference: diagnosis, prophylaxis and, treatment of osteoporosis. Am J Med. 94:646–650. 1993. View Article : Google Scholar | |
Bonjour JP, Ammann P and Rizzoli R: Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998. WHO guielelines. 9:379–393. 1999. | |
Mundy G, Garrett R, Harris S, et al: Stimulation of bone formation in vitro and in rodents by statins. Science. 286:1946–1949. 1999. View Article : Google Scholar : PubMed/NCBI | |
Yamaguchi T, Sugimoto T, Yano S, Yamauchi M, Sowa H, Chen Q and Chihara K: Plasma lipids and osteoporosis in postmenopausal females. Endocr J. 49:211–217. 2002. View Article : Google Scholar : PubMed/NCBI | |
Orozco P: Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight females. Eur J Epidemiol. 19:1105–1112. 2004. View Article : Google Scholar | |
Dennison EM, Syddall HE, Aihie Sayer A, Martin HJ and Cooper C: Lipid profile, obesity and bone mineral density: the Hertfordshire Cohort Study. QJM. 100:297–303. 2007. View Article : Google Scholar : PubMed/NCBI | |
Broulik PD and Kapitola J: Interrelations between body weight, cigarette smoking and spine bone mineral density in osteoporotic Czech females. Endocr Regul. 27:57–60. 1993.PubMed/NCBI | |
Tang YJ, Sheu WH, Liu PH, Lee WJ and Chen YT: Positive associations of bone mineral density with body mass index, physical activity and blood triglyceride level in men over 70 years old: a TCVGHAGE study. J Bone Miner Metab. 25:54–59. 2007. View Article : Google Scholar | |
Sivas F, Alemdaroǧlu E, Elverici E, Kuluǧ and Ozoran K: Serum lipid profile: its relationship with osteoporotic vertebrae fractures and bone mineral density in Turkish postmenopausal females. Rheumatol Int. 29:885–890. 2009. View Article : Google Scholar | |
Szulc P, Varennes A, Delmas PD, Goudable J and Chapurlat R: Men with metabolic syndrome have lower bone mineral density but lower fracture risk-the MINOS study. J Bone Miner Res. 25:1446–1454. 2010. View Article : Google Scholar : PubMed/NCBI | |
Samelson EJ, Cupples LA, Hannan MT, et al: Long-term effects of serum cholesterol on bone mineral density in females and men: the Framingham Osteoporosis Study. Bone. 34:557–561. 2004. View Article : Google Scholar : PubMed/NCBI | |
Tankó LB, Bagger YZ, Nielsen SB and Christiansen C: Does serum cholesterol contribute to vertebral bone loss in postmenopausal females? Bone. 32:8–14. 2003. View Article : Google Scholar | |
Hsu YH, Venners SA, Terwedow HA, et al: Relation of body composition, fat mass and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and females. Am J Clin Nutr. 83:146–154. 2006.PubMed/NCBI | |
Czerny B, Pawlik A, Juzyszyn Z and Myśliwiec Z: Effect of tamoxifen on bone mineral density and blood lipids in ovariectomized rats. Pol J pharmacol. 55:1137–1142. 2003. | |
Liu KJ, Wang WJ, Li DJ, Jin HF and Zhou WJ: Effect of Gengnianchun Recipe on bone mineral density, bone biomechanical parameters and serum lipid level in ovariectomized rats. Chin J Integr Med. 12:132–136. 2006. View Article : Google Scholar : PubMed/NCBI | |
Parhami F, Tintut Y, Beamer WG, Gharavi N, Goodman W and Demer LL: Atherogenic high-fat diet reduces bone mineralization in mice. J Bone Miner Res. 16:182–188. 2001. View Article : Google Scholar : PubMed/NCBI | |
Pelton K, Krieder J, Joiner D, Freeman MR, Goldstein SA and Solomon KR: Hypercholesterolemia promotes an osteoporotic phenotype. Am J Pathol. 181:928–936. 2012. View Article : Google Scholar : PubMed/NCBI | |
Parhami F, Mody N, Gharavi N, Ballard AJ, Tintut Y and Demer LL: Role of cholesterol biosynthetic pathway in osteoblastic differentiation of marrow stromal cells. J Miner Res. 17:1997–2003. 2002. View Article : Google Scholar | |
Xu S and Yu JJ: Beneath the minerals, a layer of round lipid particles was identified to mediate collagen calcification in compact bone formation. Biophys J. 91:4221–4229. 2006. View Article : Google Scholar : PubMed/NCBI | |
Wang Y, Tao Y, Hyman ME, Li J and Chen Y: Osteoporosis in China. Osteoporosis Int. 20:1651–1662. 2009. View Article : Google Scholar | |
Gimble JM, Robinson CE, Wu X, et al: Peroxisome proliferator-activated receptorgamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 50:1087–1094. 1996.PubMed/NCBI | |
Lecka-Czernik B, Moerman EJ, Grant DF, Lehman JM, Manolagas SC and Jilka RL: Divergent effects of selective peroxisome proliferators-activated receptor-gamma2 ligands on adipocyte versus osteoblast differentiation. Endocrinology. 143:2376–2384. 2002.PubMed/NCBI | |
Huang JT, Welch JS, Ricote M, et al: Interleukin-4-dependent production of PPAR gamma ligands in macrophages by 12/15-lipoxygenase. Nature. 400:378–382. 1999. View Article : Google Scholar : PubMed/NCBI | |
Kirkland JL, Tchkonia T, Pirtskhalava T, Han J and Karagiannides I: Adipogenesis and aging: does aging make fat go MAD? Exp Gerontol. 37:757–767. 2002. View Article : Google Scholar : PubMed/NCBI | |
Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI | |
Schoppet M, Preissner KT and Hofbauer LC: RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascularfunction. Arterioscler Thromb Vasc Biol. 22:549–553. 2002. View Article : Google Scholar : PubMed/NCBI | |
Jabbar S, Drury J, Fordham JN, Datta HK, Francis RM and Tuck SP: Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol. 64:354–357. 2011. View Article : Google Scholar : PubMed/NCBI | |
Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT and Dunstan CR: The effect of a single dose of osteoprotegerin in postmenopausal females. J Bone Miner Res. 16:348–360. 2001. View Article : Google Scholar : PubMed/NCBI | |
Mezquita-Raya P, de la Hiquera M, García DF, et al: The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal females. Osteoporos Int. 16:1368–1374. 2005. View Article : Google Scholar : PubMed/NCBI | |
Indridason OS, Franzson L and Sigurdsson G: Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int. 16:417–423. 2005. View Article : Google Scholar : PubMed/NCBI | |
Cummings SR, Martin JS, McClung MR, et al: Denosumab for prevention of fractures in postmenopausal females with osteoporosis. N Engl J Med. 361:756–765. 2009. View Article : Google Scholar : PubMed/NCBI | |
Qiu W, Andersen TE, Bollerslev J, Mandrup S, Abdallah BM and Kassem M: Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells. J Bone and Mineral Res. 22:1720–1731. 2007. View Article : Google Scholar | |
Abdallah BM and Kassem M: New factors controlling the balance between osteoblastogenesis and adipogenesis. Bone. 50:540–545. 2012. View Article : Google Scholar | |
Tamai K, Semenov M, Kato Y, et al: LDL-receptor related proteins in Wnt signal transduction. Nature. 407:530–535. 2000. View Article : Google Scholar : PubMed/NCBI | |
Bienz M: TCF: transcriptional activator or repressor? Curr Opin Cell Biol. 10:366–372. 1998. View Article : Google Scholar : PubMed/NCBI | |
Taipaleenmäki H, Abdallah BM, AlDahmash A, Säämänen AM and Kassem M: Wnt signaling mediates the cross-talk between bone marrow derived pre-adipocytic and pre-osteoblastic cell populations. Exp Cell Res. 317:745–756. 2011. View Article : Google Scholar | |
Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD and Macdougald OA: Wnt signaling stimulates osteolastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferators-activated receptor gamma. J Biol Chem. 282:14515–14524. 2007. View Article : Google Scholar : PubMed/NCBI | |
Jones SE and Jomary C: Secreted frizzled-related proteins: searching for relationships and patterns. Bioessays. 24:811–820. 2002. View Article : Google Scholar : PubMed/NCBI | |
Gaur T, Rich L, Lengner CJ, et al: Secreted frizzled related protein 1 regulates Wnt signaling for BMP2 induced chondrocyte differentiation. J Cell Physiol. 208:87–96. 2006. View Article : Google Scholar : PubMed/NCBI | |
Yao W, Cheng Z, Shahnazari M, Dai W, Johnson ML and Lane NE: Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res. 25:190–199. 2010. View Article : Google Scholar | |
Lagathu C, Christodoulides C, Tan CY, et al: Secreted frizzled-related protein 1 regulates adipose tissue expansion and is dysregulated in severe obesity. Int J Obes. 34:1695–1705. 2010. View Article : Google Scholar | |
Denver RJ, Bonett RM and Boorse GC: Evolution of leptin structure and function. Neuroendocrinology. 94:21–38. 2011. View Article : Google Scholar : PubMed/NCBI | |
Thomas T: The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol. 4:295–300. 2004. View Article : Google Scholar : PubMed/NCBI | |
Turner RT, Kalra SP, Wong CP, Philbrick KA, Lindenmaier LB, Boghossian S and Iwaniec UT: Peripheral leptin regulates bone formation. J Bone Mineral Res. 28:22–34. 2013. View Article : Google Scholar | |
Cornish J, Callon KE, Bava U, et al: Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol. 175:405–415. 2002. View Article : Google Scholar : PubMed/NCBI | |
Hamrick MW, Pennington C, Newton D, Xie D and Isales C: Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone. 34:376–383. 2004. View Article : Google Scholar : PubMed/NCBI | |
Iwaniec UT, Boghossian S, Lapke PD, Turner RT and Kalra SP: Central leptin gene therapy corrects skeletal abnormalities in leptin-deficient ob/ob mice. Peptides. 28:1012–1019. 2007. View Article : Google Scholar : PubMed/NCBI | |
Kalra SP, Dube MG and Iwaniec UT: Leptin increases osteoblast-specific osteocalcin release through a hypothalamic relay. Peptides. 30:967–973. 2009. View Article : Google Scholar : PubMed/NCBI | |
Bartell SM, Rayalam S, Ambati S, et al: Central (ICV) leptin injection increases bone formation, bone mineral density, muscle mass, serum IGF-1, and the expression of osteogenic genes in leptin-deficient ob/ob mice. J Bone Miner Res. 26:1710–1720. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ducy P, Amling M, Takeda S, et al: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 100:197–207. 2000. View Article : Google Scholar : PubMed/NCBI | |
Holloway WR, Collier FM, Aitken CJ, et al: Leptin inhibits osteoclast generation. J Bone Miner Res. 17:200–209. 2002. View Article : Google Scholar : PubMed/NCBI | |
Thomas T, Gori F, Khosla S, Jensen MD, Burguera B and Riggs BL: Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 140:1630–1638. 1999.PubMed/NCBI | |
Kim GS, Hong JS, Kim SW, Koh JM, An CS, Choi JY and Cheng SL: Leptin induces apoptosis via ERK/cPLA2/cytochrome pathway in human bone marrow stromal cells. J Biol Chem. 278:21920–21929. 2003. View Article : Google Scholar : PubMed/NCBI | |
Hamrick MW and Ferrari SL: Leptin and the sympathetic connection of fat to bone. Osteoporos Int. 19:905–912. 2008. View Article : Google Scholar | |
Hamrick MW, Della-Fera MA, Hartzell D, Pennington C and Baile CA: Intrahypothalamic injections of leptin increase adipocyte apoptosis in peripheral fat pad and in bone marrow. Cell Tissue Res. 327:133–141. 2007. View Article : Google Scholar | |
Idelevich A, Sato K and Baron R: What are the effects of leptin on bone and where are they exerted? J Bone Miner Res. 28:18–21. 2013. View Article : Google Scholar | |
Farooqi IS, Jebb SA, Langmack G, et al: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 341:879–884. 1999. View Article : Google Scholar : PubMed/NCBI | |
Paz-Filho G, Mastronardi C, Delibasi T, Wong ML and Licinio J: Congenital leptin deficiency: diagnosis and effects of leption replacement therapy. Arq Bras Endocrinol Metab. 54:690–697. 2010. View Article : Google Scholar | |
Arita Y, Kihara S, Ouchi N, et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 257:79–83. 1999. View Article : Google Scholar : PubMed/NCBI | |
Kumada M, Kihara S, Dumitsuji S, et al: Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 23:85–89. 2003. View Article : Google Scholar : PubMed/NCBI | |
Hara K, Horikoshi M, Yamauchi T, et al: Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 29:1357–1362. 2006. View Article : Google Scholar : PubMed/NCBI | |
Oshima K, Nampei A, Matsuda M, et al: Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 331:520–526. 2005. View Article : Google Scholar : PubMed/NCBI | |
Yamaguchi N, Kukita T, Li YJ, Marinez Argueta JG, Saito T, Hanazawa S and Yamashita Y: Adiponectin inhibits osteoclast formation stimulated by lipoplysaccharide from Actinobacillus actinomycetemcomitans. FEMS Immunol Med Microbiol. 49:28–34. 2007. View Article : Google Scholar | |
Kajimura D, Lee WH, Riley JK, et al: Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab. 17:901–915. 2013. View Article : Google Scholar : PubMed/NCBI | |
Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD and Liao EY: Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 21:1648–1656. 2006. View Article : Google Scholar : PubMed/NCBI | |
Tu QS, Zhang J, Dong LQ, Saunders E, Luo E, Tang J and Chen J: Adiponectin inhibits osteoclastogenesis and bone resorption via APPL1-mediated suppression of Akt1. J Bio Chem. 286:12542–12553. 2011. View Article : Google Scholar | |
Yamaguchi N, Kukita T, Li YJ, et al: Adiponectin inhibits induction of TNF-alpha/RANKL-stimulated NFATc1 via the AMPK signaling. FEBS Letters. 582:451–456. 2008. View Article : Google Scholar : PubMed/NCBI | |
Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP and Liao EY: Adiponectin stimulates human osteobalsts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res. 309:99–109. 2005. View Article : Google Scholar : PubMed/NCBI | |
Lee HW, Kim SY, Kim AY, Lee EJ, Choi JY and Kim JB: Adiponection stimulates osteoblast differentiation through induction of COX2 in mesenchymal progenitor cells. Stem Cells. 27:2254–2262. 2009. View Article : Google Scholar : PubMed/NCBI | |
Mitsui Y, Gotoh M, Fukushima N, et al: Hyperadiponectinemia enhances bone formation in mice. BMC Musculoskelet Disord. 12:182011. View Article : Google Scholar : PubMed/NCBI | |
Ealey KN, Kaludjerovic J, Archer M and Ward WE: Adiponectin is a negative regulator of bone mineral and bone strength in growing mice. Exp Biol Med (Maywood). 233:1546–1553. 2008. View Article : Google Scholar | |
Hotta K, Funahashi T, Bodkin NL, et al: Circulating concentrations of the adipocyte protein adiponetin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 50:1126–1133. 2001. View Article : Google Scholar : PubMed/NCBI | |
Bauche IB, E1 Mkadem SA, Pottier AM, et al: Overexpression of adiponectin targeted to adipose tissue in transgenic mice: impaired adipocyte differentiation. Endocrinology. 148:1539–1549. 2007. View Article : Google Scholar : PubMed/NCBI | |
Otabe S, Yuan X, Fukutani T, et al: Overexpression of human adiponectin in transgenic mice results in suppression of fat accumulation and prevention of premature death by high-calorie diet. Am J Physiol Endocrinol Metab. 293:E210–E218. 2007. View Article : Google Scholar : PubMed/NCBI | |
Williams GA, Wang Y, Callon KE, et al: In vitro and in vivo effects of adiponectin on bone. Endocrinology. 150:3603–3610. 2009. View Article : Google Scholar : PubMed/NCBI | |
Yano W, Kubota N, Itoh S, et al: Molecular mechanism of moderate insulin resistance in adiponectin-knockout mice. Endocr J. 55:515–522. 2008. View Article : Google Scholar : PubMed/NCBI | |
Nawrocki AR, Rajala MW, Tomas E, et al: Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem. 281:2654–2660. 2006. View Article : Google Scholar | |
Kubota N, Terauchi Y, Yamauchi T, et al: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 277:25863–25866. 2002. View Article : Google Scholar : PubMed/NCBI | |
Maeda N, Shimomura I, Kishida K, et al: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 8:731–737. 2002. View Article : Google Scholar : PubMed/NCBI | |
Kanazawa I: Does adiponectin have adverse effects on bone mass and fracture. Internal Med. View Article : Google Scholar : 2011. | |
Mohiti-Ardekani J, Soleymani-Salehabadi H, Owlia MB and Mohiti A: Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients. J Bone Miner Metab. 32:400–404. 2013. View Article : Google Scholar : PubMed/NCBI | |
Wu N, Wang QP, Li H, Wu XP, Sun ZQ and Luo XH: Relationships between serum adiponectin, leptin concentrations and bone mineral density and bone biochemical markers in Chinese females. Clin Chim Acta. 411:771–775. 2010. View Article : Google Scholar : PubMed/NCBI | |
Tenta R, Kontogianni MD and Yiannakouris N: Association between circulating levels of adiponectin and indices of bone mass and bone metabolism in middle-aged post-menopausal females. J Endocrinol Invest. 35:306–311. 2012. | |
Schwartz AV, Sigurdsson S, Hue TF, et al: Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults. J Clin Endocrinol Metab. 98:2294–2300. 2013. View Article : Google Scholar : PubMed/NCBI | |
Widlansky ME, Gokce N, Keaney JF and Vita JA: The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 42:1149–1160. 2003. View Article : Google Scholar : PubMed/NCBI | |
Wang GJ, Maga DB, Richemer WG, Sweet DE, Reger SI and Thompson RC: Cortisone induced bone changes and its response to lipid clearing agents. Clin Orthop. 130:81–85. 1978.PubMed/NCBI | |
Miyanishi K, Yamamoto T, Irisa T, Yamashita A, Jingushi S, Noguchi Y and Iwamoto Y: Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone. 30:185–190. 2002. View Article : Google Scholar : PubMed/NCBI | |
Zhou Q, Li Q, Yang L and Liu F: Changes of blood vessels in glucocorticoid-induced avascular necrosis of femoral head in rabbits. Zhonghua Wai Ke Za Zhi. 38:212–215. 2000.In Chinese. | |
Kitajima M, Shigematsu I, Ogawa K, Sugihara H and Hotokebuchi T: Effects of glucocorticoid on adipocyte size in human bone marrow. Med Mol Morphol. 40:150–156. 2007. View Article : Google Scholar : PubMed/NCBI | |
Kerachian MA, Séguin C and Harvey EJ: Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol. 114:121–128. 2009. View Article : Google Scholar : PubMed/NCBI | |
Savopoulos CH, Dokos CH, Kaiafa G and Hatzitolios A: Adipogenesis and osteoblastogenesis: trans-differentiation in the pathophysiology of bone disorders. Hippokratia. 15:18–21. 2011.PubMed/NCBI | |
Tsartsalis AN, Dokos C, Kaiafa GD, Tsartsalis DN, Kattamis A, Hatzitolios AI and Savopoulos CG: Statins, bone formation and osteoporosis: hope or hype? Hormones (Athens). 11:126–139. 2012. View Article : Google Scholar | |
Esposito K, Capuano A, Sportiello L, Giustina A and Giugliano D: Should we abandon statins in the prevention of bone fractures? Endocrine. 44:326–333. 2013. View Article : Google Scholar : PubMed/NCBI | |
Borton AJ, Frederick JP, Datto MB, Wang XF and Weinstein RS: The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res. 16:1754–1764. 2001. View Article : Google Scholar : PubMed/NCBI | |
Kaji H, Kanatani M, Sugimoto T and Chihara K: Stains modulate the levels of osteoprotegerin/receptor activator of NF kappaB ligand mRNA in mouse bone-cell cultures. Horm Metab Res. 37:589–592. 2005. View Article : Google Scholar : PubMed/NCBI | |
Garrett IR and Mundy GR: The role of statins as potential targets for bone formation. Arthritis Res. 4:237–240. 2002. View Article : Google Scholar : PubMed/NCBI | |
Sugiyama M, Kodama T, Konishi K, Abe K, Asami S and Oikawa S: Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun. 271:688–692. 2000. View Article : Google Scholar : PubMed/NCBI | |
Maeda T, Matsunuma A, Kawane T and Horiuchi N: Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun. 280:874–877. 2001. View Article : Google Scholar : PubMed/NCBI | |
Oxlund H, Dalstra M and Andreassen TT: Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int. 69:299–304. 2001. View Article : Google Scholar | |
Uzzan B, Cohen R, Nicolas P, Cucherat M and Perret GY: Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone. 40:1581–1587. 2007. View Article : Google Scholar : PubMed/NCBI | |
Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG and Mikhailidis DP: Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int. 20:197–207. 2009. View Article : Google Scholar | |
de Nijs RN, Jacobs JW, Lems WF, et al: Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 355:675–684. 2006. View Article : Google Scholar : PubMed/NCBI | |
Reid DM, Devogelaer JP, Saag K, et al: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trial. Lancet. 373:1253–1263. 2009. View Article : Google Scholar : PubMed/NCBI | |
Saag KG, Shane E, Boonen S, et al: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 357:2028–2039. 2007. View Article : Google Scholar : PubMed/NCBI | |
Wallach S, Cohen S, Reid DM, et al: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 67:277–285. 2000. View Article : Google Scholar : PubMed/NCBI | |
Riggs BL, Khosla S and Melton LJ III: A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal females and contributes to bone loss in aging men. J Bone Miner Res. 13:763–773. 1998. View Article : Google Scholar : PubMed/NCBI | |
Heaney RP, Recker RR and Saville PD: Menopausal changes in bone remodeling. J Lab Clin Med. 92:964–970. 1978.PubMed/NCBI | |
Manolagas SC and Jilka RL: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 332:305–311. 1995. View Article : Google Scholar : PubMed/NCBI | |
Khosla S, Atkinson EJ, Melton LJ III and Riggs BL: Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in females: a population based study. J Clin Endocrinol Metab. 82:1522–1527. 1997.PubMed/NCBI | |
D’Amelio P, Grimaldi A, Di Bella S, et al: Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone. 43:92–100. 2008. View Article : Google Scholar | |
Wells G, Tugwell P, Shea B, et al: Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal females. Endocr Rev. 23:529–539. 2002. View Article : Google Scholar : PubMed/NCBI | |
Bonnet N, Gadois C, McCloskey E, Lemineur G, Lespessailles E, Courteix D and Benhamou CL: Protective effect of beta blockers in postmenopausal females: influence on fractures, bone density, micro and macroarchitecture. Bone. 40:1209–1216. 2007. View Article : Google Scholar : PubMed/NCBI | |
Bonnet N, Benhamou CL, Brunet-lmbault B, et al: Severe bone alterations under beta2 agonist treatment: bone mass, microarchitecture and strength analyses in female rats. Bone. 37:622–633. 2005. View Article : Google Scholar : PubMed/NCBI | |
Bonnet N, Benhamou CL, Malaval L, et al: Low dose beta-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions. J Cell Physiol. 217:819–827. 2008. View Article : Google Scholar : PubMed/NCBI | |
Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E and Nicholson GC: beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res. 19:19–24. 2004. View Article : Google Scholar : PubMed/NCBI | |
Schlienger RG, Kraenzlin ME, Jick SS and Meier CR: Use of beta-blockers and risk of fractures. JAMA. 292:1326–1332. 2004. View Article : Google Scholar : PubMed/NCBI | |
Ferrari SL, Demissie S, Karasik D, Cupples LA, Imamovic A, Dupuis J and Kiel DP: Beta 2 adrenergic receptor, beta-blockers and their influence on bone mass in humans: the Framingham osteoporosis study. J Bone Miner Res. 20(Suppl 1): 11–12. 2005. | |
Rejnmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brixen K and Mosekilde L: Fracture risk in perimenopausal females treated with beta-blockers. Calcif Tissue Int. 75:365–372. 2004. View Article : Google Scholar : PubMed/NCBI |